SPC215
Atezolizumab
Status:
AfskrifuðApplication date:
22.12.2017Application published:
15.1.2018Grant published:
15.5.2019
Max expiry date:
24.9.2032Medicine name:
Tecentriq-atezolizumabMedicine for children:
No
Timeline
Today
22.12.2017Application
15.1.2018Publication
15.5.2019Registration
24.9.2032Expires
Marketing license
IS authorization number:
EU/1/17/1220/001Date:
5.10.2017
Foreign authorization number:
EU/1/17/1220Date:
21.9.2017
Owner
Name:
F. Hoffmann-La Roche AGAddress:
Grenzacherstrasse 124, Basel CH
Agent
Name:
Örn Þór slf.Address:
Klukkuvöllum 17, 221 Hafnarfirði
Patent
Number:
EP2376535